Janux Therapeutics Inc.

29.04
-0.74 (-2.48%)
At close: Mar 28, 2025, 3:59 PM
30.26
4.22%
After-hours: Mar 28, 2025, 06:17 PM EDT

Janux Therapeutics Income Statement

Year FY24 FY23 FY22 FY21 FY20 FY19
Revenue 10.59M8.08M8.61M3.64Mn/an/a
Cost of Revenue n/a1.96M841K113K13K6K
Gross Profit 10.59M6.13M7.77M3.52M-13K-6K
Operating Income -98.85M-72.98M-67.09M-32.93M-4.84M-3.77M
Interest Income 29.85M14.69M4.03M257K206K233K
Pretax Income -68.99M-58.29M-63.06M-32.67M-6.78M-4M
Net Income -68.99M-58.29M-54.15M-32.56M-5.25M-4.24M
Selling & General & Admin 41.05M26.14M22.26M10.33M1.8M772K
Research & Development 68.39M54.92M53.44M26.24M3.04M3M
Other Expenses n/an/a4.03M257K-1.74Mn/a
Operating Expenses 109.44M81.06M75.7M36.57M4.84M3.77M
Interest Expense n/an/a4.03Mn/a206K233K
Selling & Marketing Expenses n/an/an/an/an/an/a
Cost & Expenses 109.44M81.06M75.7M36.57M4.84M3.77M
Income Tax n/an/a-8.9M-113K-1.53M233K
Shares Outstanding (Basic) 53.75M44.02M41.47M41.24M41.61M41.61M
Shares Outstanding (Diluted) 53.75M44.02M41.47M41.24M41.61M41.61M
EPS (Basic) -1.28-1.32-1.31-0.79-0.13-0.1
EPS (Diluted) -1.28-1.32-1.31-0.79-0.13-0.1
EBITDA -98.85M-71.02M-66.25M-32.82M-4.83M-3.77M
Depreciation & Amortization n/a1.96M841K113K13K6K